Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $85 and keeps an Overweight rating on the shares. This was a profitable quarter for Mirum as it gradually transitions to an earnings growth story, and Cantor expects considerable inflection in EPS in 2027 and beyond, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $81 from $80 at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP
- Mirum Pharmaceuticals Reports Strong Q3 2025 Growth
- Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Mirum Pharmaceuticals reports Q3 EPS 5c, consensus (16c)